A review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation

Bibliography

• Hawksworth JS, Leeser D, Jindal RM, et al. New directions for induction immunosuppression strategy in solid organ transplantation. Am J Surg 2009;197:515-24
   PubMed Web of Science ®Google Scholar
• Padiyar A, Augustine JJ, Hricik DE. Induction antibody therapy in kidney transplantation. Am J Kidney Dis 2009;54:935-44
   PubMed Web of Science ®Google Scholar
• Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004;77:1029-33
   PubMed Web of Science ®Google Scholar
• Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy 2006;26:1771-83
   PubMed Web of Science ®Google Scholar
• Civati G, Minetti E, Busnach G, et al. Low incidence of acute rejection in kidney grafts treated with initial quadruple therapy: a retrospective analysis comparing two ATGs. Transpl Proc 1998;30:1343-5
   PubMed Web of Science ®Google Scholar
• Schnetzler B, Leger P, Völp A, et al. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients. Transpl Int 2002;15:317-25
   PubMed Web of Science ®Google Scholar
• Norrby J, Olausson M. A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplant Proc 1997;29:3135-6
   PubMed Web of Science ®Google Scholar
• Ourahma S, Talon D, Barrou B, et al. A prospective study on efficacy and tolerance of antithymocyte globulin Fresenius versus Thymoglobuline Merieux after renal transplantation. Transplant Proc 1997;29:2427
   PubMed Web of Science ®Google Scholar
• Zuckermann AO, Grimm M, Czerny M, et al. Improved long-term results with Thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 2000;69:1890-8
   PubMed Web of Science ®Google Scholar
• Schulz T, Papapostolou G, Schenker P, Kapischke M. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin. Transplant Proc 2005;37:1301-4
   PubMedGoogle Scholar
• Szczech LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a met-analysis. J Am Soc Nephrol 1997;8:1771-7
   PubMed Web of Science ®Google Scholar
• Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival: a meta-analysis of individual patient-level data. Ann Int Med 1998;128:817-26
   PubMed Web of Science ®Google Scholar
• Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of united network for organ sharing registry data. Transplantation 2010;90:1511-15
   PubMed Web of Science ®Google Scholar
• Bechstein WO, Malaise J, Saudek F, et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 2004;77:1221-8
   PubMed Web of Science ®Google Scholar
• Kuypers DRJ, Malaise J, Claes K, et al. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005;20(Suppl 2):ii33-9
   PubMedGoogle Scholar
• Malaise J, Kuypers DRJ, Claes K, et al. Immunosuppressive drugs after simultaneous pancreas-kidney transplantation. Transplant Proc 2005;37:2840-2
   PubMed Web of Science ®Google Scholar
• Opelz G, Naujokat C, Daniel V, et al. Dissociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006;81:1227-33
   PubMed Web of Science ®Google Scholar
• Ballen K. New trends in transplantation: the use of Thymoglobulin. Exprt Opin Drug Metab Toxicol 2009;5:351-5
   PubMed Web of Science ®Google Scholar
• Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76:1289-93
   PubMed Web of Science ®Google Scholar
• KyllÖnen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transplant Int 2000;13(Suppl 1):S394-8
   PubMedGoogle Scholar
• Marks WH, IIsley JN, Dharnidharka VR. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving Thymoglobulin: a systematic review. Transplant Proc 2011;43:1395-404
   PubMed Web of Science ®Google Scholar
• Rostaing L, Lavayssière L, Kamar N. Hematologic adverse effects of 2 different polyclonal antilymphocyte preparations in De Novo kidney transplant patients. Exp Clin Transplant 2010;8:178-80
   PubMed Web of Science ®Google Scholar
• Leitner J, Grabmeier-Pfistershammer K, Majdic O, et al. Interaction of antithymocyte globulins with dendritic cell antigens. Am J Transplant 2011;11:138-45
   PubMed Web of Science ®Google Scholar
• Urbanova M, Brabcova I, Girmanova E, et al. Differential regulation of the nuclear factor-κB pathway by rabbit antithymocyte globulins in kidney transplantation. Transplantation 2012;93:589-96
   PubMed Web of Science ®Google Scholar
• Pankewycz O, Leca N, Kohli R, et al. Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression. Transpl Proc 2011;43:462-5
   PubMed Web of Science ®Google Scholar
• Bell L, Girardin C, Sharma A, et al. Lymphocyte subsets during and after rabbit anti-thymocyte globulin induction in pediatric renal transplantation: sustained T cell depletion. Transpl Proc 1997;29(Suppl 7A):6S-9S
   PubMed Web of Science ®Google Scholar
• Bunn D, Lea CK, Bevan DJ, et al. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996;45:29-32
   PubMed Web of Science ®Google Scholar
• Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antithymocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995;59:1194-200
   PubMed Web of Science ®Google Scholar
• Müller TF. Long-term T cell dynamics following the use of polyclonal and monoclonal antibodies. Graft 1999;2.1(Suppl):15
   Google Scholar
• Krosgaard K, Boesgaard S, Aldershvile J, et al. Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. Scand J Infect Dis 1994;26:239-47
   PubMed Web of Science ®Google Scholar
• De Santo LS, Romano C, Mastroianni C, et al. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy. Transpl Proc 2005;37:2684-7
   PubMed Web of Science ®Google Scholar
• Taylor DO, Kfoury AG, Pisani B, et al. Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation. Transpl Proc 1997;29(Suppl 8A):13S-5S
   PubMed Web of Science ®Google Scholar
• Crespo-Leiro MG, Alonso-Pulpón L, Arizón JM, et al. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish post-heart transplant tumor registry. J Heart Lung Transplant 2007;26:1105-9
   PubMed Web of Science ®Google Scholar
• Birkeland SA, Andersen HK, Hamilton-Dutoit SJ. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of acyclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999;67:1209-14
   PubMed Web of Science ®Google Scholar
• Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:2894-900
   PubMed Web of Science ®Google Scholar
• Darenkov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848-52
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006;82:S4-8
   PubMed Web of Science ®Google Scholar
• Brophy PD, Thomas SE, McBryde KD, Bunchman TE. Comparison of polyclonal induction agents in pediatric renal transplantation. Pediatr Transplant 2001;5:174-8
   PubMed Web of Science ®Google Scholar